ImpriMed
ImpriMed combines ex vivo testing of patients' live cancer cells (its xCellSense platform) with machine learning to predict how individual patients will respond to anticancer drugs. Its main product is the Personalized Prediction Profile for canine lymphoma and leukemia, sold to veterinary oncologists. The company also offers CRO services to pharmaceutical companies and is expanding into human oncology. It was founded in 2017 and has run more than 27,000 veterinary tests as of 2026. In September 2026 it closed a $10M Series A2 bridge round that included NAVER D2SF. Total funding is reported at roughly $35M (Tracxn, CB Insights), though one aggregator lists $67M.
Funding
Every round, secondary, debt facility or acquisition involving ImpriMed that AI Lounge tracks, newest first. Latest: Series A on Sep 18, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in